Skip to content

The application of cyclopofol sedation with spontaneous breathing retained in CT-guided radiofrequency ablation

The application of cyclopofol sedation with spontaneous breathing retained in CT-guided radiofrequency ablation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104360
Enrollment
Unknown
Registered
2025-06-16
Start date
2025-06-20
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing tumor ablation surgery

Interventions

Ci-profol:Ci-ropofol group
Profol:Propofol group

Sponsors

Lishui Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Age >= 45 years, <= 80 years, gender limited; 2) Patients who received tumor ablation under CT guidance; 3) ASA grade of II~III; 4) BMI of 18 kg/m <= BMI<= 25 kg/m^2; 5) The estimated operation time was not more than 2 hours; 6) Be clear about, voluntarily participate in the study and sign the informed consent by himself or his family.

Exclusion criteria

Exclusion criteria: 1) Proposed to perform general anesthesia with endotracheal intubation; 2) The patient's SpO2 <= 95% after entering the room; 3) Patients with severe heart disease such as severe myocardial infarction within the past 6 months, heart failure within past 1 month, arrhythmias requiring treatment, angina pectoris, severe heart valve lesions, etc.; 4) Patients with severe respiratory insufficiency obstructive pulmonary disease, a history of bronchospasm requiring treatment within the past 3 months, respiratory tract infection within the past 2 weeks with obvious symptoms such as, expectoration, fever, nasal congestion, etc.; 5) Patients allergic to propofol or cyproterone; 6) Patients with schizophrenia, intellectual, mania, psychosis, long-term use of psychotropic drugs, drug addiction, history of cognitive dysfunction, etc.; 7) Patients considered unsuitable for in this experiment by the investigator.

Design outcomes

Primary

MeasureTime frame
54/2000 Incidence of respiratory-related adverse events (respiratory depression, apnea, hypoxia);Incidence of adverse events related to the circulatory system (hypotension, arrhythmia);

Secondary

MeasureTime frame
Wake-up time;Time to successful induction of sedation/anesthesia;Nausea and vomiting occurrence and severity;Drug use situation;Sedation/anesthesia satisfaction evaluation;

Countries

China

Contacts

Public ContactHao Cheng

Lishui Central Hospital

332319747@qq.com+86 579 8383 1085

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026